Accelerate Diagnostics Stock (NASDAQ: AXDX)

Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Biotech

Earnings

News

Penny Stocks

Small Cap

Markets

Trading Ideas

General

AXDX

PACB

Accelerate Diagnostics (NASDAQ: AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.

Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates

Intraday Update

Movers

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AZTR

BCDA

BFRG

CELH

CHGG

CISS

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SILK

SMCI

SOAR

VMAR

WRLD

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session.

TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.

TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

doctor-563429

Accelerate Diagnostics shares are trading lower by 38% during Friday&#39;s session. The company priced an underwritten public offering of 6,860,659 units at $1.50 each.

Why Accelerate Diagnostics (AXDX) Stock Is Down 38%

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

Press Releases

Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results

Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Aethlon Medical

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Femasys

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

INVO Fertility

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Tech

Nexalin Technology

PAVmed

Predictive Oncology

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Technologies

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tenon Medical

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Beyond Air

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Craig-Hallum

Comments

Accelerate Diagnostics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell